Tuesday, May 24, 2022
spot_img

Latest Posts

Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results – Yahoo Finance

Four clinical trials for COVID-19 and norovirus oral tablet vaccine candidates are currently ongoing

Company now operates two GMP manufacturing plants to support rapid clinical advancement of pipeline programs
Ended the quarter with $204 million in cash, cash equivalents and marketable securities
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the third quarter of 2021, reporting strong forward momentum in developing its oral vaccine platform consisting of tablet vaccines that it believes may revolutionize public health.
During the third quarter, Vaxart started the first Phase II trial of its investigational COVID-19 oral tablet vaccine and dosed its first subjects. Vaxart expects the full data set from this study to be available in Q1 2022.
Duke University published the results of its study of Vaxart’s COVID-19 vaccine candidate, finding that Vaxart’s oral tablet vaccine reduced the airborne transmission of SARS-CoV-2 virus in a hamster preclinical model.
The Company also expanded its research and manufacturing capabilities, enhancing its ability to advance its pipeline of vaccine candidates.
“Vaxart made significant progress this quarter toward its goal of developing a next-generation oral tablet COVID-19 vaccine,” said Andrei Floroiu, Vaxart’s Chief Executive Officer. “We have started our United States Phase II trial and anticipate beginning international trials in the near future. This is an important milestone, as our candidate is the only oral COVID-19 vaccine to progress to Phase II trials in the U.S.”
“Our view has been that an oral tablet vaccine could transform how the world is protected from COVID-19 and other infections because they are easy to distribute and administer. Now we added evidence suggesting the differentiated mucosal mechanism of action could be yet another improvement over injectable alternatives,” added Mr. Floroiu.
“The progress we made in our vaccine research this quarter was significant,” said Dr. Sean Tucker, Vaxart’s founder and Chief Scientific Officer. “We already learned from an earlier human influenza challenge study that our oral flu vaccine candidate inhibited the shedding of viral RNA better than injectable vaccines. Our published hamster study showed that our vaccine candidate can reduce transmission of SARS-CoV-2, even when there is infection breakthrough in a vaccinated subject.”
“The implications are significant because existing injected vaccines do not always protect against viral shedding and transmission to other people. A vaccine that reduces shedding and reduces the probability of infection could make a big difference in protecting lives and public health.”
Recent Business Highlights
Corporate Developments
Vaxart recently brought online its own GMP manufacturing facility and is now producing vaccines at two GMP plants. This has allowed the Company to manufacture all of the COVID-19 vaccine oral tablets for the clinical trials started and planned to start this year, and to begin manufacturing vaccines for its upcoming norovirus Phase II trials.
Vaxart scaled up its research, quality and manufacturing capabilities, increasing its R&D employee headcount by more than 35% during the quarter.
The Company created two advisory boards, the Scientific and Clinical Advisory Board and the Manufacturing and Quality Advisory Board, to provide expertise as the Company grows its scientific and manufacturing capabilities.
Vaxart named Dr. James F. Cummings as its Chief Medical Officer. Dr. Cummings is a board-certified infectious disease physician with extensive experience in vaccine, drug and diagnostics development, and will help guide the Company’s development of its vaccines.
Widely respected biotech executive Dr. Julie Cherrington joined Vaxart’s Board of Directors, deepening the pool of expertise on its board.

Preclinical and Clinical
Clinical COVID-19 Vaccine Developments
Vaxart made significant progress in Q3 2021 to advance its transformative approach to vaccines.
Vaxart began dosing subjects in October for its Phase II clinical trial in the United States, which is expected to enroll 96 subjects.
The Company expects data from this study to be available during Q1 2022.
The study will be conducted with subjects split evenly between COVID-19 naïve and mRNA vaccinated subjects.
During Q4 2021, Vaxart expects to start Phase Ib clinical testing in India.
The Company expects to launch additional international clinical trials in 1H 2022.

Preclinical COVID-19 Vaccine Developments
A Duke University-led study published in bioRxiv in October showed that Vaxart’s investigational oral tablet vaccine candidate reduced the airborne transmission of SARS-CoV-2 virus in a hamster model.
These results are consistent with those from Vaxart’s Phase II human flu challenge study, which showed that Vaxart’s oral tablet flu vaccine was better at reducing shedding than the injectable flu vaccine comparator.
Vaxart’s preclinical study also demonstrated that the Company’s oral vaccine platform induces robust systemic and mucosal responses.
The study suggested that mucosal vaccines may protect not only vaccinated, but also unvaccinated animals.
Vaxart will submit the results of its nonhuman primate study for publication in Q4 2021. Results from that study prompted Vaxart to move forward with its S-only vaccine candidate in Phase II clinical trials. This S-only vaccine candidate produced better antibody responses and cross-reactivity against all variants tested than Vaxart’s S+N vaccine candidate.

Norovirus Vaccine Developments
Norovirus is a highly infectious illness that affects around 20 million Americans annually, with an annual economic impact of approximately $10.5 billion in the United States.
Vaxart has almost completed enrollment in its Phase Ib placebo-controlled, dose-ranging, repeat dose trial investigating its oral norovirus vaccine candidate in elderly subjects aged 55 to 80 years. This study is designed to evaluate the safety and immunogenicity of Vaxart's vaccine candidate.
The Company anticipates completing enrollment in its norovirus VXA-G1.1-104 study in Q4 2021.
Vaxart is also conducting an additional norovirus vaccine study to evaluate the optimal timing for boost administration under VXA-NVV-105. This study has completed enrollment.
The Company expects initial data to be available from these studies in Q1 2022 and more complete data by Q2 2022.
Vaxart is preparing to launch its norovirus challenge study in Q1 2022 to evaluate the safety and clinical efficacy of its oral vaccine candidate.

Manufacturing Updates
As noted above, Vaxart is now producing vaccines at two GMP manufacturing plants in California, including its own GMP manufacturing facility.
As a result, Vaxart has produced the tablets for its Phase II and Phase Ib COVID-19 studies and is starting to produce norovirus vaccine for additional clinical studies.
Financial Results for the Three Months Ended September 30, 2021
Vaxart ended the quarter with cash, cash equivalents and available-for-sale debt securities of $204.0 million, compared to $198.9 million as of June 30, 2021. The increase was primarily due to net receipts of $20.3 million from the Company’s $250 million at-the-market facility entered into in October 2020 and $0.3 million from the exercise of warrants and options, partially offset by $14.2 million of cash used in operations and $1.3 million spent on property and equipment.
The Company reported a net loss of $17.6 million for the third quarter of 2021, compared to $8.1 million for the third quarter of 2020. Net loss per share for the third quarter of 2021 was $0.14, compared to a net loss of $0.08 per share in the third quarter of 2020. The increase in net loss per share was primarily due to the increase in net loss, resulting from a significant increase in research and development expenses.
Revenue for the third quarter of 2021 was $200,000, compared to $265,000 in the third quarter of 2020. The decrease was due to lower royalty revenue from sales of Inavir in Japan.
Research and development expenses were $12.4 million for the third quarter of 2021, compared to $4.6 million for the third quarter of 2020. The increase was mainly due to increases in headcount and related costs and in manufacturing and clinical trial expenses related to our COVID-19 and norovirus vaccine candidates.
General and administrative expenses were $5.0 million for the third quarter of 2021, compared to $4.2 million for the third quarter of 2020. The increase was mainly due to an increase in headcount and related costs.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart's strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "should," "believe," "could," "potential," "will," "expected," "plan," and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart's ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart's expectations regarding clinical results and trial data; and Vaxart's expectations with respect to the effectiveness of its product candidates. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart's product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart's product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart's or its partners' control; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain, and enforce necessary patent and other intellectual property protection; that Vaxart's capital resources may be inadequate; Vaxart's ability to resolve pending legal matters; Vaxart's ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the "Risk Factors" sections of Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.

Contacts

Vaxart Media Relations:
Investor Relations:
Mark Herr
Andrew Blazier
Vaxart, Inc.
Finn Partners
[email protected]
[email protected]
(203) 517-8957


Vaxart, Inc.
Condensed Consolidated Balance Sheets
September 30, 2021
December 31, 2020
(Unaudited)
(1)
(in thousands)
Assets
Cash and cash equivalents
$
167,231
$
126,870
Investments in debt securities
36,720

Accounts receivable
190
334
Prepaid and other assets
5,269
1,699
Property and equipment, net
5,427
1,480
Right-of-use assets, net
12,237
6,838
Intangible assets, net
14,062
15,361
Total assets
$
241,136
$
152,582
Liabilities and stockholders equity
Accounts payable
$
3,745
$
2,133
Accrued and other liabilities
4,543
4,908
Liability related to sale of future royalties
15,158
14,929
Operating lease liabilities
12,742
7,208
Total liabilities
36,188
29,178
Stockholders’ equity
204,948
123,404
Total liabilities and stockholders’ equity
$
241,136
$
152,582
(1) Derived from the audited consolidated financial statements of Vaxart, Inc. for the year ended December 31, 2020, included on the Form 10-K filed with the Securities and Exchange Commission on February 25, 2021.
Vaxart, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended September 30,
Nine Months Ended September 30,
2021
2020
2021
2020
(in thousands, except share and per share amounts)
Revenue
$
200
$
265
$
818
$
3,690
Operating expenses:
Research and development
12,409
4,616
33,219
11,272
General and administrative
5,042
4,190
16,136
10,076
Restructuring costs

(952
)

(849
)
Total operating expenses
17,451
7,854
49,355
20,499
Loss from operations
(17,251
)
(7,589
)
(48,537
)
(16,809
)
Other income and (expenses), net
(311
)
(470
)
(1,080
)
(1,345
)
Loss before income taxes
(17,562
)
(8,059
)
(49,617
)
(18,154
)
Provision for income taxes
21
26
89
205
Net loss
$
(17,583
)
$
(8,085
)
$
(49,706
)
$
(18,359
)
Net loss per share, basic and diluted
$
(0.14
)
$
(0.08
)
$
(0.41
)
$
(0.23
)
Shares used in computing net loss per share, basic and diluted
123,984,141
107,718,578
120,110,780
81,121,045

Despite the tremendous success of vaccines against the coronavirus, there's always more work to be done when it comes to reducing the risks associated with infection. If coronavirus vaccine development was the story of 2020, antiviral pill development might well be the story of 2021 and 2022. Pfizer (NYSE: PFE) is currently working on an antiviral pill for COVID-19 to add to its profitable coronavirus portfolio, where its highly successful vaccine is front and center.
Shares were mostly lower in Asia on Friday, with Chinese markets weighed down by concerns over property developers.
Peloton's stock gets pounded after a lackluster quarter and outlook. Here's why one analyst thinks it's time to buy.
Shares of semiconductor giant Qualcomm (NASDAQ: QCOM), which skyrocketed yesterday on news of a big earnings beat, maintained their momentum Friday with some help from Wall Street — rising another 5% through 11:45 a.m. EDT. At last report, a tally by TheFly.com had no fewer than five separate analysts raising price targets on Qualcomm stock yesterday, after the company reported a respectable 12% increase in revenues in its fiscal third quarter — and a 76% raise in pro forma profits. One analyst — Goldman Sachs — even went ahead and upgraded Qualcomm stock to buy, with a $192 price target.
Shares of Emergent Biosolutions (NYSE: EBS) have crashed 41.1% as of 11:44 a.m. EDT on Friday. The huge decline came after the company revealed on Thursday that a multimillion-dollar agreement with the U.S. Department of Health and Human Services (HHS) had been canceled. Emergent Biosolutions CEO Robert Kramer seemed to attempt to play down the termination of the HHS contract.
Shares of Merck & Co. tumbled 9.5% in midday trading Friday, putting them on track to suffer the biggest one-day drop since January 2005, after Pfizer Inc. released data on a pill to treat COVID-19 that showed greater efficacy than Merck's. The stock's price decline of $8.61 was shaving about 57 points off the Dow Jones Industrial Average's price, while the Dow rallied 246 points, or 0.7%. The stock's big selloff, the stock has retraced about 56% of the gain, from the Sept. 29 close of $75.11 to
Shares of the vaccine specialist Dynavax (NASDAQ: DVAX) were sliding this morning after the company reported third-quarter earnings. After the market closed on Thursday, Dynavax stock actually rose after hours on the strength of a terrific third-quarter earnings report. Yesterday, Moderna's (NASDAQ: MRNA) stock tanked after the company had to lower its revenue outlook in the face of softer vaccine demand.
Shares of cloud analytics company Teradata (NYSE: TDC) fell on Friday. Teradata stock's decline follows the company's third-quarter earnings release. While revenue and earnings per share were both ahead of analysts' consensus forecasts for the two metrics, the company missed analysts' average view for cloud annual recurring revenue.
Interestingly, some of the best deals available at the moment happen to be ultra-high-yield dividend stocks (i.e., companies with yields at or above 7%). Best of all, you don't need a boatload of cash to begin generating income or building wealth with dividend stocks. Upstream oil companies, like drillers, feel a direct pinch when crude oil or natural gas prices decline.
When looking at DocuSign, Inc. ( NASDAQ:DOCU ), investors want to know what are the next major milestones for the company. For new companies, becoming self-sufficient signals a large reduction of bankruptcy risk, as well as that the company is creating a valuable service.
In this article, we discuss the 10 dividend stocks with over 10% yield. If you want to skip our detailed analysis of these stocks, go directly to the 5 Dividend Stocks With Over 10% Yield. The Federal Reserve Bank of Dallas recently forecast that home prices and rent are likely to rise in the coming […]
Pfizer stock surged Friday after its Covid pill reduced the risk of hospitalization or death by 89%. The results sent Merck and Moderna down.
The educational technology company expects a dreadful close to its fiscal year, but there may be a silver lining.
ARK Invest went shopping on Thursday, buying into three stocks that have fallen after posting disappointing quarterly results this earnings season.
Shares of gaming company Activision Blizzard (NASDAQ: ATVI) fell 12.7% in the first four trading days this week, according to data provided by S&P Global Market Intelligence, after the company reported an underwhelming quarter. Shares fell the most on Wednesday, following the earnings report, and have tried to mount a small gain late in the week. Third-quarter 2021 results were pretty solid with revenue of $1.95 billion coming in slightly below guidance but earnings per share of $0.78 easily topping the $0.64 management had given as outlook.
Shares of COVID-19 vaccine companies Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and Ocugen (NASDAQ: OCGN) have all posted wild price fluctuations through Thursday's closing bell this week, according to data from S&P Global Market Intelligence. Specifically, Moderna's stock has fallen by 18% through the first four trading sessions this week, while Novavax's shares have plunged nearly 27% over the same period. Ocugen's stock, on the other hand, initially popped by a healthy 21.4% during Monday and Tuesday's combined trading sessions, before giving back all of these gains and then some over the next two days.
Is Pfizer stock a buy after its Covid pill cuts hospitalizations and deaths by 89% in a key study? Is PFE stock a buy right now?
Shares of Chinese electric vehicle (EV) maker Nio (NYSE: NIO) surged Thursday morning after an analyst report that included an increased price target and promising outlook. As of 10:45 a.m. EDT, Nio's American depositary receipts (ADRs) were up 4.7% after having jumped more than 6% at their highs this morning. The pop comes as a Deutsche Bank analyst boosted the automaker's price target by $10 to $70 per share.
Shares of Roku, Inc. (NASDAQ:ROKU) came under pressure on Thursday after announcing third quarter results. The results were mixed, but the company also said revenue growth would slow sharply in the fourth quarter due to supply chain constraints. Roku is priced for long term growth, and a temporary headwind shouldn’t change the long term outlook. However the stock’s high P/E ratio means investors should expect volatility for some time to come.
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be…

source

Latest Posts

spot_imgspot_img

Don't Miss

Stay in touch

To be updated with all the latest news, offers and special announcements.